Purpose : As the use of hormone replacement therapy for the menopausal women increases, some caution is advised, since there is an increased risk ofbreast cancer. Accordingly, the importance of regular mammography has been addressed. This cross-sectional study analyzed the effects of different hormone therapies on mammographic density.
Purpose : As the use of hormone replacement therapy for the menopausal women increases, some caution is advised, since there is an increased risk ofbreast cancer. Accordingly, the importance of regular mammography has been addressed. This cross-sectional study analyzed the effects of different hormone therapies on mammographic density.
Materials and Methods: Sixty-seven postemenopausal women who had completed one year ofhormone therapy and had undergone follow-up mammography, were divided into two groups: Group 1 : continuous conjugated equine estrogen, O. 625mg, plus continuous medroxyprogesterone acetate, 2.5mg (n=48), Group II : continuous conjugated equine estrogen 0.625 mg (n = 19). The mammograms were read by two radiologists.
Res비 ts : With regard to the radiologists involved, interobserver reliability (kappa) was 0.70 and intrao bserver reliability (kappa) was 0.51 and 0.67 . Before hormone therapy, factors related to decreased mammographic density were age and number of full term pregnancies (p < 0.05) . After one year ofhormone therapy, body fat showed a significant increase (p < 0.05), but in spite of this, increased mammographic density induced by hormone therapy remained significantly high (p < 0.05). Compared with Group II , Group 1 showed a significant increase in mammographic density (p < 0 .05).
In Group 1 , mammographic density increased from P2 to DY pattern in two cases, but there was no such change in Group II.
Conclusion : The increase of mammographic density seen in Group II was much more significant statistically than that seen in Group 1. The mammograms ofwomen who have undergone continuous combined hormone therapy should therefore be interpreted very cautiously.
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Increasing numbers of postmenopausal women are undergoing hormone replacement therapy (HRT) for a variety ofreasons : to relieve menopausal symptoms, to prevent menopause-induced osteoporosis, and for the beneficial effects on the prevention and prognosis of cardiovascular disease (1, 2) . Even though the risk of breast cancer is a matter of controversy, some prospec-tive studies have indicated a gradually-increasing risk of this after long term estrogen use (3, 4) ; in a significant percentage ofwomen undergoing HRT, increased breast density on mammography has also been reported (5, 6) . There are many factors affecting breast density; we analyzed the differing effects of different HRT regimens in postmenopausal women.
Subjects and Methods

Subjects
Among 1934 women who visited Yongdong Jeil Women' s hospital for their first general examination, 67 postmenopausal women who had fulfilled the following criteria were selected : 1) last menstrual period at least one year previously; 2) FSH) 4O m1U and last menstrual period at least 6 months previously; 3) no previous history of hormone replacement therapy ; 4) successful follow-up of second mammography one year after baseline mammography. These 67 women were treated for 12 months with one of two regimens : Group 1 : 48 women who received 0.625mg/day conjugated equine estrogen (CEE) (Premarin, Wyeth-Ayerst Laboratories, Radnor, PA) plus 2.5mg/day medroxyprogesterone acetate (Provera, Upjohn Co. , Kalamaz-00, MI) for 30 consecutive days, Group II : 19 women who received CEE, 0.625mg/day, for 30 consecutive days.
Mammography
Baseline craniocaudal and mediolateral oblique mammograms were obtained with a Senographe 600T (G.E. , Milwaukee, U.S. A.), using the maximum tolerated compression. All subjects underwent a follow-up mammogram, using the same equipment, one year after their first visit. All mammograms were obtained by the same radiologic technologist, who maintained strict quality control, and were evaluated by two board certified radiologists. Mammographic density was assessed according to the Wolfe classification (7, 8) : Nl , breasts composed primarily of fat; Pl , prominent ducts in the subareolar area involving approximately one-third of the breast; P2, prominent ducts involving the major portion of the breast; DY, a considerable amount of collagen or dysplasia, with or without identified ducts.
Data Analysis
An estimation of the reliability ofthe two radiologists used kappa statistics (9) to compare interobserver consistency, and 3-month interval readings ofthe same 40 films to determine intraobserver reproducibility. To assess the factors that have been shown to influence the appearance of the breast on mammograms before hormone replacement treatment (10 -12), simple correlation and multiple regression analysis were perfor med. These factors include interval since last men strual period, age at menarche, number of children, weight, body fat, and lactation. Comparisons of those factors before and after hormone therapy were performed using student's t-test for paired quantitative data. After adjustment for those factors which significantly changed after treatment, differences in mammographic changes between the two regimens were compared by ANOV A. We used the Statistical Package for Social Sciences for Windows TM(SPSS Inc, Chicago, 1L, U.S.A.) for calculation; the minimum level of statistical significance for all analyses was p (0.05.
Results
Reliability of Mammographic Readings between two Radio/ogists 1nterobserver reliability (kappa) was 0.70 while intraobserver reliability (kappa) was 0.51 and 0.67
Mean age of the study population was 58 :t 7.8 years, and median ages of menarche and menopause were 16 and 49 years, respectively. As older women disliked bleeding during hormone therapy, we had, for them, preferred to prescribe a continuous combined regimen. Table 1 clearly shows that those women who underwent this regimen were older and had a much higher body fat component than those whose therapy involved only estrogen (p (0.05).
Factors influencing Mammographic Density before Hormone Replacement Therapy (HR T) (Tab/e2)
As women aged, they had less dense breast (p = O. 002) and the more children they had, the less dense were their breasts (p=O.OOI); tall women had denser breasts (p=O.027). Age of menarche and menopause, smoking history , body weight, body fat, body mass index (BM1), and lactation were not statistically significant factors influencing mammographic change 
Mammographic Change after Hormone Replacement Therapy (HR T)
After hormone therapy, increased mammographic density was noted in both groups; it was seen in 30 of 67 postmenopausal women (44.8 %) who had undergone HRT. The mammographs of the 48 women who had undergone continuous combined HRT showed significantly increased dens띠1 in 27 cases (56 .3 %) ; this was seen in only 3 of 19 (15 .8 %) who underwent single estrogen replacement therapy (ERT) (p < 0.05) (Fig 1, 2) (Tabel 3). Because hormone therapy changes some anthropometric components, we analyzed factors inf1uencing mammographic change after HRT. Only hormone therapy itself had a significant impact on mammographic change (p = O.OOI) ( Table 4 ). In women who had undergone continuous combined HRT, two cases showed the DY pattern, which changed from P2, while there was no such change in the single ERT group.
Discussion
Previously little kaown effects of HRT, such as came to light, and this has increased demand upon this treatment. With increasing numbers ofwomen undergoing HRT, physicians are very concerned about the possible risk of breast cancer and advocate regular mammography. Mammographic change associated with HRT has been reported in many studies (6, 13 -15) , including ours, in which 44.8 % (30/67) of postmenopausal women showed increased density, a figure much higher than that ofStomper et al. (14) , who reported that 24 % (12/50) of postmenopausal women undergoing HRT showed mammographic change, or of Berkowitz et al. (15) whose data showed that change decreased or has no effect on mitotic activity and proliferation of breast epithelial cells, continues to be very controversial. Progesterone acts in synergism with estrogen on the distal portion of the ducts, favoring differentiation into acini, and promotes the growth of lobuloalveolar structures. It can reduce estrogen induced proliferation and converts the proliferative effect of estrogen on the ductal cells into cellular differ entiation (16; 17) . As ductal, periductal connective, and lobular tissue proliferates in response to a combination of estrogen and progesterone, the greatest increase in mammographic breast density would be expected in women being treated with combination had occurred in 17 % of women. Both these studies showed that treatment with both estrogen and progesterone more often led to mammographic change than treatment with estrogen alone. This latter increases the mitogenic activity of epithelial cells, which leads to duct growth; connective tissue surrounding the ducts is also very sensitive to the action of estrogen. Whether progesterone causes increased or Table 3 . Mammographic Density before & after Hormone Replacement Therapy (HRT) between Two Gro때S *Group 1 (n=48) Group n (n=19) therapy (5) . There has, however, been no report describing the likely effect of different drug combination on mammographic change. Our study showed that the continuous combined regimen we used resulted in significantly increased mammographic density after one year's treatment; we observed that mammographic density after 50 years of age, or after menopause decreased, and breast parenchyma became less dense (7, 8, 12) . Boyd et a1. (18) reported the relationship between mammographic density and hist이ogic risk factor for breast cancer, and Wolfe (7, 8) and Saftla (19) reported an increased risk of breast cancer in women with mammographically dense breasts. According to Saftla' s retrospective review of cases detected during the fifth year of the Breast Cancer Detection Demonstration 안이 ects ' (19), high risk patterns were particularly significant in women with a positive family history of breast cancer ; in those with P2 or DY patterns, the likelihood ofbreast cancer was 7.37 times higher than in those with an N1 pattern. In women with no family history, the corresponding odds ratio was 2.42. In our study, two cases who had undergone the continuous combined HRT showed a DY pattern after one year' s treatment, while there was no such change in the single ERT group. This implies that in the continuous combined HRT group, we should be alert to the risk of increased risk of breast cancer. Most postmenopausal women who underwent continuous combined therapy complained of more frequent mastalgia (data not shown) than those whose regimen was different. Plu-Bureau et a1. (20) asserted that mastalgia is an easy and early marker of breast susceptibility to estrogen, and reported that it was associated with the occurrence of breast cancer. Beca use of breast tenderness, adequate breast compression could not be performed, resulting in an apparent increase in density and a decreased sensitivity ofmammograms. In women under 50, breast density had a greater inf1uence on mammographic sensitivity than was the case in women aged 50 or over (12) ; in women with primarily fatty breasts, sensitivity was higher. Irrespective of the cause of increased density, improved quality and increased sensitivity are very important for reliable mammographic interpretation. Our study showed that mammographic density increased significantly as a result of continuous combined HRT; this treatment could thus lead to decreased m know whether increased density would disappear after a couple ofyears under the combined regimen. To be aware of further mammographic change, which might occur after the first year of treatment, a longer follow-up period is therefore needed; longitudinal observation to assess the relative risk of eventual breast cancer with the use of the continuous combined regimen is also required. In conclusion, this regimen, with estrogen and progesterone, led to a significant increase in mammographic density, compared to that seen after single estrogen therapy. To determine whether this increase remains or disappears -in other words, to determine its clinical significance -a longer follow-up period is required; after resolving such factors as mastalgia and mammographic sensitivity, further studies are therefore needed. Dense mammograms should also be interpreted more carefully.
